Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Kezar Life Sciences Inc
KZR | US
6.81
USD-0.09
-1.30%
KZR | US
Loading StockChartView...
About Kezar Life Sciences Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
17/03/2026
Close
6.81
Open
6.84
High
6.96
Low
6.80
Kezar Life Sciences Inc. a clinical-stage biotechnology company engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616) a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications including lupus nephritis dermatomyositis and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261 a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is headquartered in South San Francisco California.
View LessKZR | US
Risk
42.1
Sharpe
0.16
Luna's Score
49/100
Recommendation
Hold
Luna says (KZR | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
47.3%1 month
42.1%3 months
28.5%6 months
80.3%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.40
Debt to equity
0.12
Debt to assets
0.10
Ent. to EBITDA
0.06
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-98.46M
MarketCap
496.87M
MarketCap(USD)
496.87M
Div. yield
-
Op. margin
-1.42K
Erngs. growth
-
Rev. growth
-
Ret. on equity
-51.48
Short ratio
0.92
Short perc.
1.38
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
0.82
Range1M
1.19
Range3M
1.42
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.20
Price X volume
50.89K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.06 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.40 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 28.49 | 72.80 | Lower Risk |
| Debt to Equity | 0.12 | -1.23 | Expensive |
| Debt to Assets | 0.10 | 0.25 | Cheaper |
| Market Cap | 496.87M | 3.66B | Emerging |
